Your browser doesn't support javascript.
loading
Authors' Reply to Moura et al.: "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk".
Rajasimhan, Suraj; Pamuk, Omer; Katz, James D.
Affiliation
  • Rajasimhan S; Clinical Pharmacy Specialist-Pharmacotherapy, Pharmacy Department, National Institutes of Health Clinical Center, 10 Center Drive, Bldg. 10, Room 1C240, Bethesda, MD, 20892, USA. suraj.rajasimhan@nih.gov.
  • Pamuk O; Office of the Clinical Director, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Katz JD; Office of the Clinical Director, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Drugs Aging ; 38(6): 539-541, 2021 06.
Article in En | MEDLINE | ID: mdl-33871805
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thromboembolism / Janus Kinase Inhibitors Type of study: Etiology_studies / Risk_factors_studies Limits: Aged / Humans Language: En Journal: Drugs Aging Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thromboembolism / Janus Kinase Inhibitors Type of study: Etiology_studies / Risk_factors_studies Limits: Aged / Humans Language: En Journal: Drugs Aging Year: 2021 Document type: Article